TW201831187A - 新穎醫藥組成物 - Google Patents

新穎醫藥組成物 Download PDF

Info

Publication number
TW201831187A
TW201831187A TW106137040A TW106137040A TW201831187A TW 201831187 A TW201831187 A TW 201831187A TW 106137040 A TW106137040 A TW 106137040A TW 106137040 A TW106137040 A TW 106137040A TW 201831187 A TW201831187 A TW 201831187A
Authority
TW
Taiwan
Prior art keywords
cyclodextrin
hydroxypropyl
combination
sulfobutyl ether
dissolving agent
Prior art date
Application number
TW106137040A
Other languages
English (en)
Chinese (zh)
Inventor
高斯特 坎貝爾
法蘭西可 亨利奎茲
Original Assignee
瑞士商諾華股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50828398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW201831187(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 瑞士商諾華股份有限公司 filed Critical 瑞士商諾華股份有限公司
Publication of TW201831187A publication Critical patent/TW201831187A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
TW106137040A 2012-11-30 2013-11-28 新穎醫藥組成物 TW201831187A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261731597P 2012-11-30 2012-11-30
US61/731,597 2012-11-30

Publications (1)

Publication Number Publication Date
TW201831187A true TW201831187A (zh) 2018-09-01

Family

ID=50828398

Family Applications (2)

Application Number Title Priority Date Filing Date
TW102143365A TW201434468A (zh) 2012-11-30 2013-11-28 新穎醫藥組成物
TW106137040A TW201831187A (zh) 2012-11-30 2013-11-28 新穎醫藥組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TW102143365A TW201434468A (zh) 2012-11-30 2013-11-28 新穎醫藥組成物

Country Status (28)

Country Link
US (2) US20150328320A1 (enExample)
EP (2) EP2925299B1 (enExample)
JP (1) JP6232443B2 (enExample)
KR (1) KR102206432B1 (enExample)
CN (2) CN107970214A (enExample)
AR (1) AR093648A1 (enExample)
AU (1) AU2013352369B2 (enExample)
BR (1) BR112015012111A8 (enExample)
CA (1) CA2891346A1 (enExample)
CL (1) CL2015001459A1 (enExample)
EA (2) EA028246B1 (enExample)
ES (1) ES2686730T3 (enExample)
IL (3) IL300664A (enExample)
IN (1) IN2015DN04094A (enExample)
MA (1) MA38121A1 (enExample)
MX (1) MX2015006867A (enExample)
MY (1) MY170427A (enExample)
NZ (1) NZ628395A (enExample)
PE (1) PE20151024A1 (enExample)
PH (1) PH12015501168A1 (enExample)
PL (1) PL2925299T3 (enExample)
PT (1) PT2925299T (enExample)
SG (1) SG11201503688SA (enExample)
TN (1) TN2015000198A1 (enExample)
TW (2) TW201434468A (enExample)
UY (1) UY35157A (enExample)
WO (1) WO2014085371A1 (enExample)
ZA (1) ZA201503346B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102293907B1 (ko) 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
US20200178569A1 (en) * 2016-04-29 2020-06-11 Alvin Kershman Method of Coating an Edible Thermoplastic Pet Chew
CA3041561A1 (en) 2016-11-25 2018-05-31 Jiangsu Hengrui Medicine Co., Ltd. Pyridone derivative pharmaceutical composition and preparation method thereof
KR102230721B1 (ko) * 2019-02-01 2021-03-22 주식회사 오스코텍 피리도피리미딘계 염산염을 포함하는 경구용 고형제제 및 이의 제조방법
WO2021081554A1 (en) * 2019-10-22 2021-04-29 Chemistryrx Methods for treating congenital epidermal hyperplasia
AU2022414970A1 (en) * 2021-12-15 2024-06-27 Sillajen, Inc. Pharmaceutical compositions comprising modified beta-cyclodextrins
WO2023219465A1 (ko) * 2022-05-12 2023-11-16 주식회사 지뉴브 안정한 액상 제약 제제
WO2025132408A2 (en) 2023-12-21 2025-06-26 Synthon B.V. Solvates of trametinib

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6077871A (en) * 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
CA2569850C (en) * 2004-06-11 2011-04-05 Toshiyuki Sakai 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido [2,3-d] pyrimidine derivatives and related compounds for the treatment of cancer
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
PL1819353T3 (pl) * 2004-12-07 2011-07-29 Onyx Therapeutics Inc Kompozycja do hamowania proteasomu
CN1872055A (zh) * 2005-06-01 2006-12-06 李�杰 适合儿童应用的阿莫西林与盐酸氨溴索的复方制剂及其处方和制备方法
ES2364491T5 (es) * 2005-10-26 2015-02-19 Cydex Pharmaceuticals, Inc. Composiciones de sulfoalquiléter ciclodextrina y métodos de preparación de las mismas
EP2476461A3 (en) * 2007-01-16 2012-10-24 BiPar Sciences, Inc. Formulations For Cancer Treatment
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
CN101352419B (zh) * 2007-07-26 2010-08-11 天津药物研究院 一种醋溴茶碱无糖型颗粒剂及其制备方法
KR101478779B1 (ko) * 2007-11-22 2015-01-05 에스케이케미칼주식회사 재수화시간이 향상된 택산 유도체 함유 동결건조 조성물 및이의 제조방법
AU2010306653B2 (en) 2009-10-16 2013-10-24 Novartis Ag Combination
EP2638043B1 (en) 2010-11-11 2017-06-07 Bayer Intellectual Property GmbH Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
US20130023531A1 (en) 2011-01-27 2013-01-24 Boehringer Ingelheim International Gmbh Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors
CA2820709C (en) 2011-02-28 2016-02-16 Sunshine Lake Pharma Co., Ltd. Substituted quinoline compounds and methods of use
JP5906303B2 (ja) * 2011-04-07 2016-04-20 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Ａｋｔキナーゼ阻害剤としてのイミダゾピリダジン類
CN102600132B (zh) * 2012-03-13 2014-05-14 齐鲁制药有限公司 一种含氨磺必利的口服制剂
CN102626394A (zh) * 2012-03-15 2012-08-08 合肥科大生物技术有限公司 一种精氨酸布洛芬颗粒剂及其制备方法

Also Published As

Publication number Publication date
PH12015501168A1 (en) 2015-08-10
MA38121A1 (fr) 2016-10-31
EA201591047A1 (ru) 2015-11-30
IL238971B (en) 2019-05-30
AU2013352369A1 (en) 2015-05-28
CN104902876B (zh) 2018-01-19
CA2891346A1 (en) 2014-06-05
BR112015012111A2 (pt) 2017-07-11
EP3400933A1 (en) 2018-11-14
JP2016501874A (ja) 2016-01-21
KR20150091352A (ko) 2015-08-10
CN107970214A (zh) 2018-05-01
EP2925299B1 (en) 2018-06-06
IL300664A (en) 2023-04-01
WO2014085371A1 (en) 2014-06-05
SG11201503688SA (en) 2015-06-29
BR112015012111A8 (pt) 2018-01-23
PE20151024A1 (es) 2015-07-27
KR102206432B1 (ko) 2021-01-22
AR093648A1 (es) 2015-06-17
EP2925299A1 (en) 2015-10-07
PT2925299T (pt) 2018-10-16
MY170427A (en) 2019-07-31
AU2013352369B2 (en) 2016-07-28
TN2015000198A1 (en) 2016-10-03
IL266415B2 (en) 2024-03-01
ES2686730T3 (es) 2018-10-19
IN2015DN04094A (enExample) 2015-10-09
ZA201503346B (en) 2016-01-27
EA028246B1 (ru) 2017-10-31
IL238971A0 (en) 2015-07-30
PL2925299T3 (pl) 2018-11-30
EP2925299A4 (en) 2016-06-29
JP6232443B2 (ja) 2017-11-15
MX2015006867A (es) 2015-10-05
TW201434468A (zh) 2014-09-16
CN104902876A (zh) 2015-09-09
HK1209047A1 (en) 2016-03-24
IL266415B1 (en) 2023-11-01
US20150328320A1 (en) 2015-11-19
NZ628395A (en) 2016-10-28
EA201791411A1 (ru) 2018-03-30
US20170189408A1 (en) 2017-07-06
IL266415A (en) 2019-06-30
CL2015001459A1 (es) 2015-12-18
UY35157A (es) 2014-06-30

Similar Documents

Publication Publication Date Title
CN103998041B (zh) 药物组合物
KR102206432B1 (ko) 신규 제약 조성물
US20230105887A1 (en) Novel pharmaceutical composition
HK1259834A1 (en) Novel pharmaceutical trametinib composition
HK1209047B (en) Novel pharmaceutical composition
RU2779429C2 (ru) Новая фармацевтическая композиция
CN104902896A (zh) 组合
KR20160127754A (ko) Btk 억제제 및 akt 억제제를 포함하는 조합물